Wikipedia -WSS

Wikipedia

author：knowledge 2025-09-27 13:04:14 - browse：2

TRENTON, N.J. — Pharma industry giants including Bristol Myers Squibb, Johnson & Johnson, Novartis, and Novo Nordisk deployed a half-dozen lawyers to a courtroom here Thursday in a bid to dismantle Medicare’s new drug price negotiation program, just hours before President Biden is set to glorify it in his State of the Union.

A federal judge in New Jersey heard an unusual quadruple oral argument in which attorneys for all four drugmakers combined forces to challenge different facets of the Inflation Reduction Act, which in 2022 empowered Medicare to negotiate the prices of a small number of drugs each year beginning in 2026.

Over four hours, the debate spanned most of the substantive issues that pharmaceutical companies and their allies have raised across the country, both in constitutional challenges to the law and in challenges to how Medicare officials have interpreted the law so far. That means the court’s decision in these cases could produce a first substantive test for several of the arguments that haven’t been addressed by courts in other states, where companies like Boehringer Ingelheim, AstraZeneca, and Merck are also suing, separately, over the same law.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： New guidelines on severe brain injury complicate already difficult decisions

hotspot

WSS

At JPM 2024, hospital systems pitch financial strength to investors

JPM pitch from hospitals? Revenue streams outside of patient care

The strategy behind pharma's lawsuits over drug pricing reform

JPM 2024: Biotech’s most prolific dealmaker sees a rosy 2024

Merck to acquire Harpoon Therapeutics for $680 million

Allen Institute goes after foundational questions, CEO Costa says

focus

Wikipedia

leisure time

In Memoriam: Notable people who died in 2023

Does Paxlovid work in people vaccinated against Covid

Walensky prepares to leave CDC — and Congress — behind

New guidelines on severe brain injury complicate already difficult decisions

Moonlake's readout produced a cash windfall. Risks remain

Medicare Advantage coverage denials need scrutiny, senators say

Peter Hotez and the public health issue of online harassment

The story of mRNA: From a loose idea to a tool that may help curb Covid

Trump demands the U.S. pay no more for drugs than other countries … again

Stories you might have missed in 2023: health, science, medicine

focus

FDA early review: GLP

Paxlovid study fails to answer questions over benefit for broader groups

Disclosing genetic information: not as worrisome as once feared

Gene therapy denied for Afghan refugee whose father aided U.S.

A preacher's new calling: Diversifying neuroscience research

In areas with more Black doctors, Black people live longer

knowledge

hotspot

hotspot

Wikipedia